Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

Main Article Content

Judit Demeter
Julia Weisinger
Zsolt Nagy

Keywords

chronic myeloid leukemia, TKI, COVID-19

Downloads

Download data is not yet available.
Abstract 515 | PDF Downloads 197 HTML Downloads 73

References

[1.] Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, Merkely G, Karády J, Várkonyi I, Papp C, Miseta A, Betlehem J, Burián K, Csóka I, Vásárhelyi B, Ludwig E, Prinz G, Sinkó J, Hankó B, Varga P, Fülöp GÁ, Mag K, Vokó Z; HUNgarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. Geroscience. 2020 ; 42(4):1063-1074.
https://doi.org/10.1007/s11357-020-00226-9.
[2]. Kemenesi G, Kornya L, Tóth GE, Kurucz K, Zeghbib S, Somogyi BA, Zöldi V, Urbán P, Herczeg R, Jakab F. Nursing homes and the elderly regarding the COVID-19 pandemic: situation report from Hungary. Geroscience. 2020 ; 1–7. https://doi.org/10.1007/s11357-020-00195-z.
[3].Abruzzese E, Luciano L, D’Agostino F, Trawinska M, Pane F, De Fabritiis P. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in infection. Mediterr J Hematol Infect Dis 2020 ;12(1): e2020031, DOI: http://dx.doi.org/10.4084/MJHID.2020.031
[4].Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V, Petrucci L, Serrao A, Salaroli A, Alimena G. Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis. 2011 ;3(1):e2011021.
https://doi.org/10.4084/mjhid.2011.021
[5].Sorà F, Chiusolo P, Laurenti L, Innocenti I, Autore F, Alma E, Viscovo M, Fusco D, Maresca M, Tumbarello M, Sica S. SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation. Transfus Apher Sci. 2020 ; 102881.
https://doi.org/10.1016/j.transci.2020.102881.
[6]. Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, You Y, Chen Z, Chen S, Wan C, Zhu X, Chang W, Sheng L, Cheng H, Zhang Y, Li Q, Qin J; Hubei Anti-Cancer Association, Meng L, Jiang Q. Leukemia. 2020 ;34(7):1799-1804. https://doi.org/10.1038/s41375-020-0853-6.
[7]. Ba?c? S, Ata N, Altunta? F, Yi?eno?lu TN, Dal MS, Korkmaz S, Namdaro?lu S, Ba?türk A, Hac?bekiro?lu T, Do?u MH, Berber ?, Dal K, Erkurt MA, Turgut B, Ça?layan M, Ayval? MO, Çelik O, Ülgü MM, Birinci ?; Turkish Ministry of Health, Hematology Scientific Working Group. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020; 26(7):1676-1682. https://doi.org/10.1177/1078155220953198
[8]. Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, Fava C, Galimberti S, Gozzini A, Gugliotta G, Iurlo A, Latagliata R, Luciano L, Pregno P, Rege-Cambrin G, Rosti G, Stagno F, Tiribelli M, Foà R, Saglio G; Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Campus CML working group. Leukemia. 2020;34(8):2260-2261. https://doi.org/10.1038/s41375-020-0904-z.